Benefits
Weight management and visceral fat in obese women
A 16-week double-blind randomized placebo-controlled trial in non-diabetic obese premenopausal women on an energy-restricted diet used 600 mg/day Xanthigen® (300 mg pomegranate seed oil + 300 mg brown seaweed extract with 2.4 mg fucoxanthin). It found significant weight loss, body fat reductions, and ~3 cm waist reduction, with no adverse reactions over 16 weeks.
NAFLD liver fat content reduction
The trial enrolled women with NAFLD (liver fat >11%) plus a group with normal liver fat (<6.5%); the NAFLD subgroup is particularly important. Liver fat content was reduced, and ALT, AST, and GGT plasma levels were reduced — clinically relevant for fatty liver disease where pharmacological options are limited. Particularly compelling given the unmet need in NAFLD.
Resting energy expenditure increase ~400 kcal/day
The trial documented an increase in resting energy expenditure of approximately 400 kcal/day in the active group. Distinctive thermogenic mechanism via fucoxanthin's UCP1-mediated white-to-brown adipose tissue browning, different from caffeine-based stimulant thermogenics. Provides a non-stimulant thermogenic option.
Blood lipid profile improvements
The trial also reported blood lipid profile improvements. Multi-domain metabolic effects align with the proposed multi-mechanism action.
Inflammatory markers and blood pressure
The trial reported inflammatory marker improvements plus blood pressure improvements. Cardiometabolic-syndrome-relevant endpoints alongside the weight and liver outcomes.
Synergistic patented combination (mechanism)
The combination provides multi-target weight management benefits beyond either component alone: fucoxanthin (UCP1-mediated thermogenesis) + pomegranate seed oil (punicic acid conjugated linolenic acid + antioxidant + cardiovascular effects). The synergistic positioning differentiates Xanthigen® from generic fucoxanthin or pomegranate seed oil supplements.
Pomegranate seed oil punicic acid antioxidants
Pomegranate seed oil is rich in punicic acid (a conjugated linolenic acid, 18:3 n-5) supporting cholesterol modulation, insulin sensitivity, and anti-inflammatory effects. Mechanistic complement to fucoxanthin's thermogenic action.
Mechanism of action
Fucoxanthin UCP1-mediated thermogenesis
Fucoxanthin (an allenic carotenoid) induces UCP1 expression in white adipose tissue, driving white-to-brown adipose tissue browning. Browned adipose tissue oxidizes fatty acids for heat rather than ATP, increasing energy expenditure — the mechanism for the observed ~400 kcal/day REE rise. Distinguishing thermogenic mechanism among weight-management supplements.
PPARγ and C/EBPs adipogenesis transcription factor down-regulation
Xanthigen® suppresses preadipocyte differentiation and adipogenesis through down-regulation of PPARγ and C/EBP transcription factors. Mechanistic basis for the body fat reduction beyond simple thermogenesis.
SIRT-1, AMPK, and FoxO pathway modulation
Research also documented SIRT-1, AMPK, and FoxO pathway modulation — multi-pathway metabolic regulation including longevity-associated SIRT-1 activation and AMPK-driven fatty acid oxidation.
Punicic acid (pomegranate) effects
Pomegranate seed oil punicic acid (conjugated linolenic acid 18:3 n-5) supports cholesterol modulation, insulin sensitivity, and anti-inflammatory effects. Distinct mechanism complementing fucoxanthin's thermogenic action.
Fucoxanthin antioxidant activity
Fucoxanthin is a strong singlet oxygen quencher and free radical scavenger. Antioxidant mechanism contributing to the broader metabolic benefits.
Hepatoprotective effects
ALT, AST, and GGT improvements in the NAFLD subgroup reflect hepatoprotective activity — likely combining direct fatty acid oxidation effects with anti-inflammatory mechanisms.
Clinical trials
Clinical evidence on Xanthigen® (Fucoxanthin + Pomegranate Seed Oil) for the indications and outcomes described.
premenopausal women
Abidov M et al. 2010 (Diabetes Obes Metab 12(1):72-81). 16-week double-blind randomized placebo-controlled trial in 151 non-diabetic obese premenopausal women — 113 with NAFLD (liver fat >11%) plus 38 with normal liver fat (<6.5%). 600 mg/day Xanthigen® on 1,800 kcal/day diet. Significant weight loss, body fat reductions, ~3 cm waist reduction; liver fat reduction in NAFLD subgroup; ALT/AST/GGT reductions; REE increased ~400 kcal/day; blood lipid, inflammatory marker, and blood pressure improvements. No adverse reactions. Foundational human trial supporting both weight management and NAFLD applications.
Clinical evidence on Xanthigen® (Fucoxanthin + Pomegranate Seed Oil) for the indications and outcomes described.
Clinical population described in trial publication.
Lee J et al. 2012 (J Agric Food Chem 60(4):1094-1101). Mechanism study — Xanthigen® suppresses preadipocyte differentiation and adipogenesis through down-regulation of PPARγ and C/EBP transcription factors, plus modulation of SIRT-1, AMPK, and FoxO pathways. Comprehensive molecular characterization supporting the body fat reduction observation.
Clinical evidence on Xanthigen® (Fucoxanthin + Pomegranate Seed Oil) for the indications and outcomes described.
Clinical population described in trial publication.
Maeda H et al. 2006 (Int J Mol Med 18(1):147-152). Foundational fucoxanthin pharmacology — fucoxanthin and its metabolite fucoxanthinol suppress adipocyte differentiation in 3T3-L1 cells. Preclinical mechanism work that motivated the Xanthigen® clinical development.